GlassScriptPhysician profile
Jill Suzanne Mazurek
NPI 1972678852
$2,697.87
in general payments reported to CMS, 2019-2025
27 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $132 · 2021: $371 · 2022: $380 · 2023: $437 · 2024: $653 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $478.95 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $287.26 | 2019-2025 | |
| Neuraxis, INC. | $229.24 | 2023 | |
| Sanofi Pasteur INC. | $216.15 | 2019-2025 | |
| Adlon Therapeutics L.P. | $204.66 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $178.97 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $170.91 | 2019-2025 | Gardasil 9, Vaxneuvance, Enflonsia |
| Almirall LLC | $136.32 | 2019 | |
| Corium, LLC | $119.06 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $114.11 | 2019-2024 | Jornay Pm |
| Cranial Technologies, INC | $109.20 | 2019-2025 | Doc Band |
| Genentech USA, INC. | $68.95 | 2019-2021 | |
| Shire North American Group INC | $48.53 | 2019 | |
| Seqirus USA INC | $47.19 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $35.13 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $34.34 | 2019 | |
| Collegium Pharmaceutical, INC. | $33.19 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $31.56 | 2021-2024 | Adzenys Xr-Odt |
| Ars Pharmaceuticals Operations, INC. | $23.00 | 2025 | Neffy |
| Biomarin Pharmaceutical INC. | $22.48 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.00 | 2019 | |
| Biomerieux INC | $17.51 | 2025 | Biofire Spotfire Control Station |
| Verrica Pharmaceuticals INC. | $17.44 | 2025 | Ycanth |
| Tris Pharma INC | $14.54 | 2021 | |
| Glaxosmithkline, LLC. | $14.08 | 2020 | |
| Kaleo, INC. | $13.07 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Mazurek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.